Inhibition of naive Th1CD4+ T cells by glatiramer acetate in multiple sclerosis

被引:15
作者
Kantengwa, S.
Weber, M. S.
Juillard, C.
Benkhoucha, M.
Fellay, B.
Zamvil, S. S.
Gougeon, M.-L.
Chofflon, M.
Lalive, P. H.
机构
[1] Univ Hosp Geneva, Dept Neurol, Neuroimmunol Labs, CH-1211 Geneva 14, Switzerland
[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[3] Univ Geneva, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland
[4] Univ Hosp Fribourg, Dept Chem & Haematol, Fribourg, Switzerland
[5] Inst Pasteur, Dept Mol Med, Antiviral Immun Biotherapy & Vaccine Unit, Paris, France
关键词
multiple sclerosis; glatiramer acetate; T-cell differentiation; CD4(+) T cell; CD8(+) T cell;
D O I
10.1016/j.jneuroim.2006.12.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated whether glatiramer acetate (GA) treatment may affect Th1 differentiation at various T-cell maturation stages. Specifically, we analyzed the effect of in vivo GA treatment on intracellular synthesis of IL-2 and TNF-alpha by naive, memory and effector CD4(+) and CD8(+) T cells by five-colour flow cytometry. Our data indicate that GA treatment downregulates/normalizes an accelerated Th1 differentiation of CD4(+) T cells in RRMS patients at all stages of T-cell maturation. Most notably, we conclude that, by altering naive, unprimed CD4(+) T cells, GA treatment appears to affect T-cell differentiation, at least in part, in an antigen-independent manner. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 48 条
  • [1] Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ
    Aharoni, R
    Kayhan, B
    Eilam, R
    Sela, M
    Arnon, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) : 14157 - 14162
  • [2] Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate
    Azoulay, D
    Vachapova, V
    Shihman, B
    Miler, A
    Karni, A
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2005, 167 (1-2) : 215 - 218
  • [3] BAARS PA, 1995, J IMMUNOL, V154, P17
  • [4] Bitsch A, 2000, GLIA, V29, P366, DOI 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO
  • [5] 2-Y
  • [6] Burns J, 1999, ANN NEUROL, V45, P33, DOI 10.1002/1531-8249(199901)45:1<33::AID-ART7>3.0.CO
  • [7] 2-G
  • [8] Monitoring multiple sclerosis course and activity with TNF-alpha
    Chofflon, M
    Fellay, B
    [J]. MULTIPLE SCLEROSIS, 1998, 4 (03): : 188 - 192
  • [9] Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease
    Clerici, M
    Saresella, M
    Trabattoni, D
    Speciale, L
    Fossati, S
    Ruzzante, S
    Cavaretta, R
    Filippi, M
    Caputo, D
    Ferrante, P
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2001, 121 (1-2) : 88 - 101
  • [10] Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
    Duda, PW
    Schmied, MC
    Cook, SL
    Krieger, JI
    Hafler, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) : 967 - 976